| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A Case Report of Successful Treatment With Crizotinib to Overcome Resistance to Osimertinib in an EGFR Mutated Non–Small-Cell Lung Cancer Patient Harboring an Acquired MET Exon 14 Mutation
|
Pinquie, François
|
|
|
23 |
2 |
p. e131-e134
|
artikel
|
| 2 |
Actionability of on-target ALK Resistance Mutations in Patients With Non-Small Cell Lung Cancer: Local Experience and Review of the Literature
|
Koopman, Bart
|
|
|
23 |
2 |
p. e104-e115
|
artikel
|
| 3 |
Arginase Pathway Markers of Immune-Microenvironment in Thymic Epithelial Tumors and Small Cell Lung Cancer
|
Umemura, Shigeki
|
|
|
23 |
2 |
p. e140-e147
|
artikel
|
| 4 |
Benefit of Concurrent Versus Sequential Chemoradiotherapy in Elderly Patients With Stage III Non-Small Cell Lung Cancer
|
Logtenberg, Marleen E.
|
|
|
23 |
2 |
p. 116-121
|
artikel
|
| 5 |
Care Patterns for Stereotactic Radiosurgery in Small Cell Lung Cancer Brain Metastases
|
Gjyshi, Olsi
|
|
|
23 |
2 |
p. 185-190
|
artikel
|
| 6 |
Comments on “Lobe-specific Lymph Node Dissection in Clinical Stage IA Solid-dominant Non-small-cell Lung Cancer: A Propensity Score Matching Study”
|
Takamori, Shinkichi
|
|
|
23 |
2 |
p. e135-e136
|
artikel
|
| 7 |
Comparative Efficacy and Safety of TKIs Alone or in Combination With Antiangiogenic Agents in Advanced EGFR-Mutated NSCLC as the First-Line Treatment: A Systematic Review and Meta-Analysis
|
Zhang, Shuang
|
|
|
23 |
2 |
p. 159-169
|
artikel
|
| 8 |
dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score ≥50%
|
Holtzman, Liran
|
|
|
23 |
2 |
p. 122-134
|
artikel
|
| 9 |
Dorian Gray Syndrome of Upfront Immunotherapy in Patients With Non–Small-Cell Lung Cancer and High PD-L1 Expression
|
Hendriks, Lizza E.L.
|
|
|
23 |
2 |
p. e87-e89
|
artikel
|
| 10 |
Editorial Board
|
|
|
|
23 |
2 |
p. A1
|
artikel
|
| 11 |
Efficacy and Safety of Combined Brain Radiotherapy and Immunotherapy in Non-Small-Cell Lung Cancer With Brain Metastases: A Systematic Review and Meta-Analysis
|
Yang, Yin
|
|
|
23 |
2 |
p. 95-107
|
artikel
|
| 12 |
EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy
|
Shah, Manan P.
|
|
|
23 |
2 |
p. e148-e153
|
artikel
|
| 13 |
Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets
|
Tu, Hai-Yan
|
|
|
23 |
2 |
p. 135-142
|
artikel
|
| 14 |
Increased Disparities in Patients Diagnosed with Metastatic Lung Cancer Following Lung CT Screening in the United States
|
Ganesh, Ashwin
|
|
|
23 |
2 |
p. 151-158
|
artikel
|
| 15 |
Lipoid Pneumonia After Pembrolizumab Treatment for Advanced Non–Small-Cell Lung Cancer
|
Yaga, Moto
|
|
|
23 |
2 |
p. e116-e117
|
artikel
|
| 16 |
Longitudinal Assessment of Health Utility Scores, Symptoms and Toxicities in Patients with Small Cell Lung Cancer Using Real World Data
|
Kuehne, Nathan
|
|
|
23 |
2 |
p. e154-e164
|
artikel
|
| 17 |
NaPi2b expression in a large surgical Non-Small Cell Lung Cancer (NSCLC) cohort
|
Heynemann, S
|
|
|
23 |
2 |
p. e90-e98
|
artikel
|
| 18 |
Near-Complete Response to Combined Pembrolizumab and Platinum-Doublet in a Patient With STK11/KRAS Mutated Advanced Lung Adenocarcinoma
|
Pathak, Ranjan
|
|
|
23 |
2 |
p. e137-e139
|
artikel
|
| 19 |
Nomogram Predicting Overall Survival Benefit of Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer
|
Jacobs, Corbin D.
|
|
|
23 |
2 |
p. 177-184
|
artikel
|
| 20 |
Quality of Life in Octogenarians After Lung Resection Compared to Younger Patients
|
Asemota, Nicole
|
|
|
23 |
2 |
p. e118-e130
|
artikel
|
| 21 |
Risk Factors for Lung Cancer in an Underrepresented Safety-Net Screening Cohort
|
Singh, Sarah
|
|
|
23 |
2 |
p. e165-e170
|
artikel
|
| 22 |
Safety and Efficacy of Extended Interval Dosing for Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer During the COVID-19 Pandemic
|
Hijmering-Kappelle, L.B.M.
|
|
|
23 |
2 |
p. 143-150
|
artikel
|
| 23 |
Table of Contents
|
|
|
|
23 |
2 |
p. A3-A6
|
artikel
|
| 24 |
The new era of immune checkpoint inhibition and target therapy in early-stage non-small cell lung cancer. A review of the literature
|
Catania, Chiara
|
|
|
23 |
2 |
p. 108-115
|
artikel
|
| 25 |
The Role of Thoracic Surgeon in the Fight Against COVID-19 Pandemic Frontline
|
Zhou, Yaodong
|
|
|
23 |
2 |
p. 91-94
|
artikel
|
| 26 |
Tumor Shrinkage With Combination of Alectinib and Trastuzumab in a Patient With ALK-Rearranged Non–small Cell Lung Cancer Harboring HER2-Amplification as an Acquired Resistance Mechanism to ALK Inhibitor Therapy
|
Tsui, David Chun Cheong
|
|
|
23 |
2 |
p. e99-e103
|
artikel
|
| 27 |
VATS Versus Open Lobectomy in Pathological T1 SCLC: A Multi-Center Retrospective Analysis
|
Xu, Jinming
|
|
|
23 |
2 |
p. 170-176
|
artikel
|
Tijdschrift beschrijving